None
Conditions
Interventions
Nalbuphine <=0.05mg/kg:N/A
0.05 < nalbuphine <=0.075mg/kg:N/A
0.075 < nalbuphine <=0.1mg/kg:N/A
Sponsors
Suizhou Central Hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Age over 65 years old, gender not limited; 2) Scheduled digestive endoscopy diagnosis and treatment (including gastroscopy, colonoscopy, etc.); 3) American Society of Anesthesiologists (ASA) classification: I-III; 4) No history of allergy to anesthetic drugs; 5) Patients voluntarily joined this study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1) Age <65 years old; 2) There are severe disorders of heart, lung, liver and kidney functions; 3) Have a history of mental illness or cognitive dysfunction and be unable to cooperate with research; 4) Have a history of opioid abuse; 5) There are acute complications such as gastrointestinal bleeding and perforation, which require emergency surgical treatment; 6) Known or suspected gastrointestinal obstruction (including paralytic ileus) exists; 7) Have used any drugs that may affect the results of this study within the recent period (within one month); 8) Other circumstances where the researcher deems it unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemodynamics and respiratory function stability;Indicators of anesthesia timeliness;Analgesic and sedative quality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Specific concerns: The incidence of adverse events;The addition and total dosage of propofol/etomidate complex solution; | — |
Countries
China
Contacts
Public ContactYou Hua
Suizhou Central Hospital
Outcome results
None listed